Medicilon Assists Longsee Biomedical's LF01 capsules approved for clinical use

On November 20, LF01, an innovative anti-tumor drug independently developed by Longsee Biomedical Co. Ltd. (Longsee Biomedical), received the NMPA drug clinical trial approval notice.